Abstract

BackgroundThe physical health and quality of life of the elderly are severely affected by osteoporosis (OP). MethodsWe explored the regulatory mechanism of ICA in vivo and in vitro by constructing OP rats and inducing osteogenic differentiation of BMSCs. First, we determined the expression of miR-335–5p in bone tissues of OP patients, bone tissues of OP rats, and osteogenic BMSCs by RT-qPCR. Alizarin red staining was employed to detect the formation of calcium nodules in the cells. MTT was used to detect cell viability. Finally, we detected the bone tissue changes in OP rats by overexpression of miR-335–5p or oral ICA. ResultsmiR-335–5p was lowly expressed in bone tissues of OP patients and OP rats. ICA treatment reversed the inhibitory effect of miR-335–5p inhibitor on BMSCs matrix mineralization. Moreover, PTEN was verified to be a downstream effector of miR-335–5p. During ICA induction, overexpression of PTEN reversed the promotive effect of miR-335–5p mimics on the osteogenic differentiation of BMSCs. In vivo experiments also found that overexpression of miR-335–5p or ICA treatment improved the pathogenesis of OP in rats. ConclusionICA improved OP by up-regulating miR-335–5p to inhibit PTEN, thereby providing a new strategy for the prevention and treatment of OP.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.